New Delhi, October 22:

Covaxin, India’s first indigenously-developed vaccine candidate against coronavirus (COVID-19), has been cleared by the Drugs Controller General of India (DCGI) for the third phase of clinical trials. Covaxin is developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR). The anti-coronavirus vaccine candidate had shown positive results in preliminary trials.

Bharat Biotech, a Hyderabad-based vaccine maker, had applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission to conduct Phase 3 trials for its COVID-19 vaccine candidate.